Axsome Therapeutics (AXSM) Prices 2M Share Offering at $87
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq futures fall after record Samsung profit fails to calm AI chip worries
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
December 19, 2019 7:05 AM ESTNEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM) (Axsome or the Company), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $87.00 per share. The proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Axsome, are expected to be $174.0 million. In addition, Axsome has granted the underwriters a 30-day option to purchase up to... More
